This study utilized a prospectively collected cohort of RRMS patients and controls to discover and validate an alteration in the concentrations of innate immunity-related molecules—TLR3 and TLR4-—in circulating EVs of MS patients. The gene discussed is TLR3; the disease is myeloid sarcoma.